| scholarly article | Q13442814 |
| P50 | author | Elisabeth de Vries | Q64712784 |
| Marjolijn N Lub-de Hooge | Q90690146 | ||
| Anton G T Terwisscha van Scheltinga | Q130278922 | ||
| Arjan Kol | Q130279162 | ||
| P2093 | author name string | Steven de Jong | |
| Christian A Gerdes | |||
| Martin Pool | |||
| P2860 | cites work | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 |
| Lung cancer signatures in plasma based on proteome profiling of mouse tumor models | Q24628852 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. | Q30650378 | ||
| ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics | Q33601653 | ||
| Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma | Q33767100 | ||
| ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116 | Q34223890 | ||
| Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology | Q34762185 | ||
| Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. | Q35748692 | ||
| The epidermal growth factor receptor conundrum | Q35942163 | ||
| Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. | Q35956405 | ||
| Epidermal growth factor receptor targeting in cancer | Q36557269 | ||
| Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. | Q36609565 | ||
| Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer | Q37091185 | ||
| Characterization of Glycosylation Sites of the Epidermal Growth Factor Receptor | Q37396323 | ||
| Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab | Q37696629 | ||
| 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. | Q38286469 | ||
| Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. | Q39408529 | ||
| Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. | Q39903960 | ||
| Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells | Q39953010 | ||
| In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. | Q40107068 | ||
| Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody | Q40177482 | ||
| Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole | Q40430170 | ||
| A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. | Q40677094 | ||
| PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab | Q41541247 | ||
| AMIDE: a free software tool for multimodality medical image analysis | Q42614465 | ||
| Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma | Q42629419 | ||
| 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. | Q43097928 | ||
| Production of an Epidermal Growth Factor Receptor-Related Protein | Q44454765 | ||
| GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab | Q44823741 | ||
| Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation | Q44907727 | ||
| Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging | Q44944204 | ||
| Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
| Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. | Q50595029 | ||
| 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. | Q53057899 | ||
| Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. | Q53265601 | ||
| Monoclonal Antibodies Specific for Peptide Epitopes of the Epidermal Growth Factor Receptor's Extracellular Domain | Q53442709 | ||
| Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors | Q58614658 | ||
| Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma | Q68184538 | ||
| Improved in vivo stability and tumor targeting of bismuth-labeled antibody | Q68840510 | ||
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer | Q71059676 | ||
| Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer | Q78969303 | ||
| Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer | Q81709409 | ||
| P433 | issue | 42 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 68111-68121 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab | |
| P478 | volume | 7 |
| Q43992554 | 89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment |
| Q91967339 | Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer |
| Q39389369 | Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. |
| Q90581932 | ImmunoPET: Concept, Design, and Applications |
| Q90697923 | PET Imaging of Receptor Tyrosine Kinases in Cancer |
| Q47661007 | Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. |
| Q90690154 | Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate |
| Q57285764 | Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition |
Search more.